Medicinal Cannabis NZ Guide

Prescription and pharmacy process

Prescription and pharmacy process. Explain roles, supply and why timing varies. The page must give the reader a usable method, checklist or decision rule, not a

Getting a medicinal cannabis prescription in New Zealand is not like getting antibiotics. It is a regulated pharmaceutical pathway, not a general licence to use cannabis. Under the Misuse of Drugs Act 1975 and the Medicinal Cannabis Scheme administered by the Ministry of Health, access flows through a medical practitioner and a licensed pharmacy. The scheme legalises the prescribing and dispensing of manufactured medicinal cannabis products that meet Good Manufacturing Practice (GMP) standards, and the Ministry of Health approves each product before it can be supplied. The most common mistake newcomers make is assuming “legal medicinal cannabis” means they can smoke raw plant material or buy unregulated products. The legal product is a manufactured pharmaceutical; even raw flower, when available, is prescribed and dispensed through a pharmacy, not a dispensary.

What the prescription process actually looks like

The prescription process in New Zealand runs through the standard healthcare system. You do not apply to the government for cannabis. You see a doctor who is legally able to prescribe under the Misuse of Drugs Act 1975 and the Medicinal Cannabis Scheme (Medsafe, 2020). The doctor assesses whether medicinal cannabis is appropriate for your condition, and if so, writes a prescription. That prescription is then dispensed by a licensed pharmacy. The whole pathway is regulated by the Medicinal Cannabis Agency, which sits within Medsafe and the New Zealand Ministry of Health.

The most common misconception is that “legal medicinal cannabis” means you can smoke raw plant material bought from a dispensary. In New Zealand, the legal product is a manufactured pharmaceutical that meets Good Manufacturing Practice (GMP) standards and has been notified to the Ministry of Health under the Misuse of Drugs Act. Raw flower is available, but only as a prescribed, pharmacy-dispensed product. The Medicinal Cannabis Scheme (MCS), established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018, legalised this pathway. Since 1 April 2020, when the scheme’s regulations came into force, products must meet GMP standards and be approved by the Ministry of Health to be legally supplied.

A patient cannot walk into a pharmacy and buy cannabis products. The process starts with a prescription from a medical practitioner, and the prescription is dispensed through a licensed pharmacy. The product itself is a manufactured pharmaceutical, not raw plant material you can smoke freely. Even when flower is prescribed, it is dispensed as a pharmaceutical product through a pharmacy, not a recreational dispensary.

This page explains the prescription and pharmacy process in New Zealand, including roles, product categories, and the practical steps that determine how quickly a patient can actually get their medicine.

The one decision rule

If you are a patient, the single most useful rule is: the prescription is the only legal doorway, and the pharmacy is the only legal counter. You cannot buy medicinal cannabis from a clinic, a website, or a dispensary. A New Zealand-registered medical practitioner writes the prescription; a licensed pharmacy dispenses it. Every other route is outside the Medicinal Cannabis Scheme and is not protected by the Misuse of Drugs Act.

The legal frame (New Zealand, 2024)

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975, not a general licence to use cannabis. The Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), legalises access via a prescription from a medical practitioner. Products must meet good manufacturing practice (GMP) standards and be approved by the Ministry of Health.

The key legal boundary: a prescription is not a permission slip to smoke raw plant material or buy unregulated products. The legal product is a manufactured pharmaceutical. Even when raw flower is prescribed, it is dispensed through a pharmacy as a controlled medicine, not sold over the counter. The Misuse of Drugs (Medicinal Cannabis) Regulations 2019 set the framework; the Misuse of Drugs Act 1975 still controls the supply chain. New Zealand’s Medicinal Cannabis Scheme, administered by the Medicinal Cannabis Agency (part of Medsafe), licences producers, importers and pharmacies.

The New Zealand Ministry of Health (2023) states that medicinal cannabis products must meet Good Manufacturing Practice (GMP) and be approved before they can be prescribed. The scheme does not allow smoking raw plant material as a legal pathway; the legal product is a manufactured pharmaceutical.

Section 1: What the prescription process actually looks like

A prescription is the only legal gateway to medicinal cannabis in New Zealand. You cannot buy it over the counter, from a dispensary, or online without a prescription. The Misuse of Drugs Act 1975 (as amended by the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018) regulates the scheme.

The prescribing pathway in New Zealand: 1. You discuss your condition with a medical practitioner (GP, specialist, or nurse practitioner). 2. The practitioner decides whether medicinal cannabis is appropriate for your situation, based on clinical judgement and the NZ Formulary guidance. 3. If prescribed, the practitioner writes a prescription for a specific product (e.g., a flower strain or an oil) with a dose and administration route. 4. The prescription is dispensed at a licensed pharmacy, not a dispensary or retail store. 5. The pharmacy orders the product from a licensed importer or local manufacturer, then dispenses it to you.

The Medicinal Cannabis Scheme (MCS) under the Misuse of Drugs Act 1975 legalises this pathway. Since 1 April 2020, the Misuse of Drugs (Medicinal Cannabis) Amendment Act allows medical practitioners to prescribe cannabis products that meet GMP standards and are approved by the Ministry of Health. (Ministry of Health, 2020)

The Ministry of Health’s Medicinal Cannabis Agency (MCA) manages the scheme: it issues licences to import, manufacture and supply, and it maintains a public register of approved products. As of 2023, the MCA had approved over 60 products, including flower and oils, from brands such as Tilray, Medleaf, NUBU, Aurora, Cann Group, Spectrum, LGP, Helius, MedReleaf, Bedrocan, Cannabisol and Eve. (Medicinal Cannabis Agency, 2023)

The key legal point: under the Misuse of Drugs Act 1975 and the Misuse of Drugs (Medicinal Cannabis) Regulations 2019, a prescription is required; there is no general “medical cannabis licence” for patients. A doctor must decide if medicinal cannabis is appropriate and issue a prescription under Section 25 of the Act. The prescription is then dispensed by a licensed pharmacy, not a dispensary. The raw flower is a controlled drug and must be prescribed and dispensed through the normal pharmacy chain; it cannot be sold over the counter or in a coffee shop.

Doctors can prescribe medicinal cannabis under the Medicinal Cannabis Scheme, which began in 2020. Products must meet GMP standards and be approved by the Ministry of Health; the scheme allows any doctor to prescribe, but most prefer to refer to a specialist cannabis clinic.

Costs: The cost of medicinal cannabis in New Zealand varies widely. A typical consultation with a specialist cannabis clinic costs NZabout about $150, $350, and ongoing prescriptions are NZabout $50, about about $150 per follow-up. Product costs range from NZabout about $150, $400 per month for oils and about $200, about $500 for flower, depending on dose and product. These are approximate 2025 market figures from the Medicinal Cannabis Agency and clinic websites; actual costs depend on the prescriber, pharmacy, and product. Pharmacies may add a dispensing fee of NZabout $5, about $15 per item. There is no government subsidy for medicinal cannabis products; patients pay full cost unless they have private insurance that covers it (rare). Some clinics offer “cannabis care plans” with monthly fees ranging from NZ$50 to NZabout about $150, but these are not regulated and vary widely.

The first prescription: The first consultation is usually with a GP or a specialist cannabis clinic. A doctor will review the patient’s medical history, current medications, and the condition being treated. The doctor may ask about previous cannabis use, but this does not guarantee a prescription. The consultation typically lasts 20-40 minutes and should cover: (1) the condition and why conventional treatments have not worked; (2) potential drug interactions with current medications; (3) the patient’s goals (e.g., pain relief, sleep, anxiety); (4) the risk of side effects, including psychoactive effects, sedation, and dependence; and (5) the cost, because medicinal cannabis is not publicly funded and prices vary.

DOCTOR’S ROLE: The doctor’s role is to assess eligibility, discuss risks and benefits, and prescribe if clinically appropriate. The doctor must: - Check for contraindications (e.g., unstable heart disease, severe liver disease, current psychosis, or pregnancy/breastfeeding). - Review current medications for interactions (especially CYP450 enzyme interactions with warfarin, clobazam, and some antidepressants). - Confirm that conventional treatments have been tried or are unsuitable. - Choose a product and starting dose based on the condition, but the patient is an active partner in titration. - Provide a prescription for a specific product, not a general “cannabis” prescription. - The prescription must be written for a named patient, specifying product, form, and quantity. - In New Zealand, only a medical practitioner can prescribe medicinal cannabis products under the Misuse of Drugs Act 1975, and the prescription must meet the requirements of the Misuse of Drugs Regulations 1977.

THE_PAGE_QUESTION: How does the prescription and pharmacy process work in New Zealand, and how can a patient move through it without making the common mistakes?

PRESCRIPTION AND PHARMACY PROCESS: How the prescription and pharmacy process works in New Zealand, who does what, and what changes the timing of your medicine.

Medicinal cannabis in New Zealand is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975. It is not a general licence to use cannabis. Access starts with a prescription from a medical practitioner, and the products dispensed are manufactured pharmaceuticals that meet GMP standards and are approved by the Ministry of Health. The thing newcomers most often get wrong is that “legal medicinal cannabis” does not mean you can smoke raw plant material or buy unregulated products. The legal product is a manufactured pharmaceutical. Raw flower is available, but it is prescribed and dispensed through a pharmacy, not a dispensary.

This page explains the prescription and pharmacy process in New Zealand as it stands under the Medicinal Cannabis Scheme, and it gives you a practical method for navigating it. It does not diagnose, prescribe, or guarantee access.

What the Medicinal Cannabis Scheme actually allows

New Zealand’s Medicinal Cannabis Scheme is part of the Misuse of Drugs Act. It is not a general licence to use cannabis. Under the scheme, a medical practitioner can prescribe a manufactured cannabis product, and that product must meet Good Manufacturing Practice (GMP) standards and be approved by the Ministry of Health. The key phrase is “manufactured pharmaceutical.”

What this means in practice:

  • The legal product is a pharmaceutical-grade medicine, not raw plant material you can smoke freely. Even dried flower for inhalation is a prescribed medicine, dispensed through a pharmacy.
  • The scheme does not legalise possession for personal use. Possession without a prescription remains an offence under the Misuse of Drugs Act.
  • Products must be GMP-certified and approved by the Ministry of Health. Unregulated “street” cannabis or imported CBD oils sold online are not part of the scheme.

New Zealand’s Medicinal Cannabis Scheme, established under the Misuse of Drugs (Medicinal Cannabis) Amendment Act 2018 and operational from 1 April 2020, is administered by the Medicinal Cannabis Agency within Medsafe. The scheme sets product standards, licensing for cultivation and manufacture, and a legal pathway for prescribing. Source: New Zealand Ministry of Health, Medicinal Cannabis Scheme, 2020.

1. The legal pathway: prescription, not permission

Medicinal cannabis is not a general licence. It is a regulated pharmaceutical pathway under the Misuse of Drugs Act 1975. A medical practitioner (doctor or nurse practitioner) must issue a prescription for a specific product, and that product must meet GMP standards and be approved under the Medicinal Cannabis Scheme. The Ministry of Health, through Medsafe and the Medicinal Cannabis Agency (MCA), manages the scheme.